Total medical costs of treating femoral neck fracture patients with hemi- or total hip arthroplasty: a cost analysis of a multicenter prospective study
verfasst von:
P. T. P. W. Burgers, M. Hoogendoorn, E. A. C. Van Woensel, R. W. Poolman, M. Bhandari, P. Patka, E. M. M. Van Lieshout, on behalf of the HEALTH trial investigators
The aim of this study was to determine the total medical costs for treating displaced femoral neck fractures with hemi- or total hip arthroplasty in fit elderly patients. The mean total costs per patient at 2 years of follow-up were €26,399. These results contribute to cost awareness.
Introduction
The absolute number of hip fractures is rising and increases the already significant burden on society. The aim of this study was to determine the mean total medical costs per patient for treating displaced femoral neck fractures with hemi- or total hip arthroplasty in fit elderly patients.
Methods
The population was the Dutch sample of an international randomized controlled trial consisting of femoral neck fracture patients treated with hemi- or total hip arthroplasty. Patient data and health care utilization were prospectively collected during a total follow-up period of 2 years. Costs were separated into costs for hospital care during primary stay, hospital costs for clinical follow-up, and costs generated outside the hospital during rehabilitation. Multiple imputations were used to account for missing data.
Results
Data of 141 participants (mean age 81 years) were included in the analysis. The 2-year mortality rate was 19 %. The mean total cost per patient after 10 weeks of follow-up was €15,216. After 1 and 2 years of follow-up the mean total costs were €23,869 and €26,399, respectively. Rehabilitation was the main cost determinant, and accounted for 46 % of total costs. Primary hospital admission days accounted for 22 % of the total costs, index surgery for 11 %, and physical therapy for 7 %.
Conclusions
The main cost determinants for hemi- or total hip arthroplasty after treatment of displaced femoral neck fractures (€26,399 per patient until 2 years) were rehabilitation and nursing homes. Most of the costs were made in the first year. Reducing costs after hip fracture surgery should focus on improving the duration and efficiency of the rehabilitation phase.
The online version of this article (doi:10.1007/s00198-016-3484-z) contains supplementary material, which is available to authorized users.
Introduction
The major complication of osteoporosis is the clinical manifestation of a hip fracture. Based upon global trends and demographic changes the worldwide number of hip fractures is expected to be over 7.3 million patients in the year 2050 [1, 2]. In The Netherlands the number of patients sustaining a hip fracture has more than doubled since 1981 to almost 19,000 patients in 2012 [3]. Almost 60 % of all proximal femoral fractures concern the femoral neck and 80 % of these fractures are displaced [4]. The Garden classification is frequently used for describing femoral neck fractures in the elderly [5]. Garden type 3 and 4 represent displaced fractures. Femoral neck fractures can be treated using a non-operative approach, internal fixation, or arthroplasty. The arthroplasty group includes hemiarthroplasty and total hip arthroplasty. Approximately 62 % of patients aged 65 years or older are primarily treated with arthroplasty; hemiarthroplasty is performed in this group in 78 % of patients on average [6]. Different insights into the preferred treatment of femoral neck fractures are the subject of ongoing international debate [7]. An international survey revealed that 75 % of the responding surgeons prefer primary arthroplasty for patients over 60 years of age with a displaced fracture. For patients under 60 years of age with a displaced fracture (Garden type 3 or 4), hemiarthroplasty was preferred by 11 % and 25 % of respondents, respectively [7]. Although initial costs for arthroplasty are higher than for internal fixation, arthroplasty has been proven to be a cost-effective therapy [8‐11].
According to data of the Dutch Ministry of Health, Welfare and Sports, hip fracture-associated crude total cost in The Netherlands was €471.5 million in 2011 [12]. Insight into health care use and associated costs is gaining importance as the burden of health care costs threatens to exceed the financial resources available. Such insight may reveal options for cutting down health care expenses. Although surgeons are expected to have a general idea about the costs for treatments they provide, these data are not easily available [13‐15]. Recently, data became available on the total medical costs of femoral neck fracture patients treated with internal fixation in The Netherlands [16]. To the best of our knowledge, detailed analysis of the costs of hemi- or total hip arthroplasty for femoral neck fractures in The Netherlands has not been published before. Therefore, the aim of this study was to provide a detailed overview of the costs consumed by patients with a displaced femoral neck fracture that was treated with hemi- or total hip arthroplasty.
Anzeige
Patients and methods
This cost study was conducted as a cohort study alongside the Dutch sample of the HEALTH trial (hip fracture evaluation with alternatives of total hip arthroplasty versus hemiarthroplasty, NCT00556842), an international randomized controlled trial comparing total hip arthroplasty and hemiarthroplasty on revision surgery and quality of life in patients with a displaced femoral neck fracture. The local medical research ethics committees of all participating centers approved the study. Informed consent was obtained from all individual participants included in the study.
Population
In The Netherlands, 14 hospitals participated and enrolled 150 patients between December 15, 2008 and February 14, 2011. Patients were eligible if they: (1) were adults aged ≥50 years, (2) had a (radiologically confirmed) displaced femoral neck fracture (ICD-10 code S72.0; Garden type 3 and 4) after a low energy impact and no other major trauma, (3) were operated within 3 days of presenting to the emergency room, and (4) were ambulatory pre-fracture (with or without aid). Patients provided informed consent. Patients were excluded if they: (1) were not suitable for treatment with arthroplasty (i.e., inflammatory arthritis, rheumatoid arthritis, pathologic fracture, or severe osteoarthritis of the hip), (2) had infection or retained hardware around the affected hip, (3) had a bone metabolism disorder other than osteoporosis, (4) were moderately or severely cognitively impaired pre-fracture, (5) had dementia or Parkinson’s disease severe enough to compromise the rehabilitation process, or (6) were not likely to be able to complete follow-up.
Treatment and follow-up
Medical optimization was warranted for all included patients before surgery. Within 72 h after presenting to the emergency department, patients were treated with hemi- or total hip arthroplasty. The exact treatment including material choice (cemented or uncemented and unipolar or bipolar prosthesis) was left to the treating surgeon. Antibiotic prophylaxis and thromboprophylaxis were prescribed to all patients according to local protocols. Post-operative weight bearing was as tolerated and early mobilization was encouraged. All patients were screened and treated for osteoporosis if deemed necessary. Follow-up measurements were performed at 10 weeks and at 6, 9, 12, 18, and 24 months after the primary surgery.
Cost measurement
This study included the following categories for hip-related costs: (1) hospital costs during primary hospital stay, including emergency department visit, diagnostic evaluations, surgery, and admission days; (2) hospital costs during follow-up, including diagnostic evaluations, outpatient clinic visits, diagnosis and treatment of adverse events, revision surgery, and admission days; and (3) non-hospital costs of rehabilitation and aids.
Anzeige
Data on health care use were collected prospectively at each scheduled follow-up contact and at the close-out visit at the end of the study. Data were collected from the study case report forms (items are listed in electronic supplementary material (ESM) Supplemental Table 1) and from the patient’s hospital file. At each follow-up contact, patients were asked to complete a questionnaire on their health care use. This questionnaire was a customized version of the “Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness” (Tic-P), which has been validated for use in health care cost studies [16, 17]. An English version of the TicP questionnaire is available online [18]. The questionnaire included questions on stay in a hospital, rehabilitation center or nursing facility, number of contacts with an intramural medical specialist or paramedical worker during admission and follow-up, medication use, comorbidity and use of walking aids. Missing data were collected during the close-out visit at each hospital.
The total number of consumption units per cost category was multiplied by the unit prices. All unit prices were indexed with the national consumer price index to 2012 and are presented in Table 1. Costs for the index surgery, including time spent in the operating room, theater personnel, overhead, anesthesia, and implant material and general equipment, was provided by two teaching hospitals and one academic hospital. Data from the teaching hospitals were averaged in order to obtain a realistic estimate of the average prices in the participating teaching hospitals. Reference cost prices of most other health care resources were derived from the Dutch manual on cost research, methods and standard costs in economic health care evaluations [19]. The NZa (Nederlandse Zorgautoriteit; Dutch Health care Authority) is the Dutch market regulator in care and advises the Minister on health care costs. This institute provided the unit prices for intramural diagnostic procedures. Costs of medication were derived from the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), which is online accessible on www.medicijnkosten.nl. Costs of rehabilitation aids were obtained from a local home care firm that is a representation of national practice. Costs of aids were calculated according to the annuity method, applying an interest rate of 4.5 % and a 10-year write-off period. With over 90 % of the patients in the study being retired, the costs for production losses were considered of limited importance for this population, and were thus excluded. Home care was also excluded, since it was impossible to determine which proportion of the total home care received was due to the hip fracture. As done previously in a similar study on internal fixation of femoral neck fractures, costs of osteoporosis screening were included in radiology/diagnostic studies costs, costs of visits to an osteoporosis specialist were included in outpatient clinic-visit costs, and costs for osteoporosis treatment were included in medication costs.
Table 1
Sources and unit costs of health care resources
Cost categories
Unit
Source of consumption data
Source of value
Unit price (€)
Hospital costs—primary stay
Emergency department visit
Visit
Hospital registry
Cost manuala
160.34
Radiology/diagnostic modalities
X-ray
X-ray
Hospital registry
NZab
54.14
CT-scan pelvis
CT-scan
Hospital registry
NZab
238.25
MRI scan pelvis
MRI scan
Hospital registry
NZab
274.16
Ultrasound
Ultrasound
Hospital registry
NZab
86.07
DEXA scan
DEXA scan
Hospital registry
NZab
114.52
Skeletal scintigraphy
Scintigraphy
Hospital registry
NZab
194.37
Surgery
Surgeon
Hour
Study registry (CRF)
Cost manuala
143.88c/109.37d
Operating roome
Hour
Study registry (CRF)
Hospital/industry dataf
738.60c/885.00d
Equipment and implant
Cemented hemiarthroplasty
Operation
Study registry (CRF)
Hospital/industry dataf
1362.00c/1197.73d
Cemented total hip arthroplasty
Operation
Study registry (CRF)
Hospital/industry dataf
1465.75c/1684.45d
Uncemented total hip arthroplasty
Operation
Study registry (CRF)
Hospital/industry dataf
NA/2041.80d
Admission days
Day
Study registry (CRF)
Cost manuala
610.57c/461.91d
Hospital costs—follow-up
Radiology/diagnostic modalities
As described above
Outpatient clinic visits
Visit
Hospital registry + questionnaireg
Cost manuala
136.98c/67.96d
Adverse events
Medicationh
Dose per day
Hospital registry/questionnaireg
CVZi
Variable
Emergency
Visit
Hospital registry
Cost manuala
160.34
Brace
Piece
Hospital registry/questionnaireg
Hospital/industry dataf
440.39
Admission days
Day
Study registry (CRF)
Cost manuala
610.57c/461.91d
Revision surgery
Surgeon
Hour
Study registry (CRF)
Cost manuala
143.88c/109.37d
Operating roome
Hour
Study registry (CRF)
Hospital/industry dataf
738.60c/885.00d
Equipment and implant
Cemented hemiarthroplasty
Operations
Study registry (CRF)
Hospital/industry dataf
1362.00c/1197.73d
Cemented total hip arthroplasty
Operations
Study registry (CRF)
Hospital/industry dataf
1465.75c/1684.45d
Uncemented total hip arthroplasty
Operations
Study registry (CRF)
Hospital/industry dataf
NA/2041.80d
Cup revision
Operations
Study registry (CRF)
Hospital/industry dataf
773.09
Open fenestration/bursectomy
Operations
Study registry (CRF)
Hospital/industry dataf
524.20
Open reduction (OR)
Operations
Study registry (CRF)
Hospital/industry dataf
333.96
Closed reduction (ER)
Operations
Study registry (CRF)
Hospital/industry dataf
160.34
Antibiotic beads
Operations
Study registry (CRF)
Hospital/industry dataf
324.83
Admission days
Days
Study registry (CRF)
Hospital/industry dataf
610.57c/461.91d
Medicationj
Dose per day
Hospital registry/questionnaireg
CVZi
NA
Costs related to rehabilitation/changes in living situation
Rehabilitation center/nursing home
Elderly home
Days
Patient questionnaireg
Cost manuala
95.57
Nursing home
Days
Patient questionnaireg
Cost manuala
252.73
Rehabilitation clinic
Days
Patient questionnaireg
Cost manuala
361.04
Home nursing day
Days
Patient questionnaireg
Cost manuala
46.72
Physical therapy (outpatient)
Hour
Patient questionnaireg
Cost manuala
Physical therapy
Session
Patient questionnaireg
Cost manuala
38.23
Use of aids
Crutches
Day
Patient questionnaireg
Home care firmk
0.07
Walker
Day
Patient questionnaireg
Home care firmk
0.08–0.15
Wheelchair
Day
Patient questionnaireg
Home care firmk
0.27
Electric scooter
Day
Patient questionnaireg
Home care firmk
0.70
Extra bed
Day
Patient questionnaireg
Home care firmk
1.22
Extra toilet facilities
Day
Patient questionnaireg
Home care firmk
0.10–0.20
Extra shower facilities
Day
Patient questionnaireg
Home care firmk
0.10–0.18
Reference unit costs anno 2012 were used, or costs were adjusted to 2012 costs by using the national consumer price index
NA not applicable
aCost manual—manual on cost research, methods and standard costs in economic health care evaluations, version 2010 [16]
bNZa; Nederlandse Zorgautoriteit (Dutch Health care Authority) standard costs
cAcademic hospital
dGeneral hospital
eIncluding operating room personnel, anesthesia, and overhead costs
fHospital/industry data; costs were requested from one academic hospital, three regional hospitals, and one surgical equipment and implant firm. Means were calculated and used as an estimation of the real costs in all participating sites
gPatient questionnaire—customized version of the “Trimbos and iMTA questionnaire on costs associated with psychiatric illness” [17]
hMainly antibiotics and in-hospital thrombosis profylaxis
iCVZ—standard prices were used as described by the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), online available on www.medicijnkosten.nl
jHip fracture-related medication only (i.e., pain medication and anti-osteoporosis medication; see ESM Supplemental Table 2 for details)
kHome care firm; costs of aids were requested from a home care firm and costs per day were calculated based on the calculated daily annuity. These costs were used as an estimation of the real costs in all participating patients
Statistical analysis
Data were analyzed using SPSS (version 20.0, SPSS Inc., Chicago, IL, USA). Replacement of missing values for cost items was done with multiple imputations following the predictive mean matching method, using ten imputations [20]. The following variables were included in the imputation model: sex, age, ASA at baseline, walking independently at baseline, treatment, costs of initial surgery, and all other cost categories at 10 weeks and at 6, 9, 12, 18, and 24 months. Each of the ten complete datasets were further analyzed by non-parametric bootstrapping using 1000 bootstraps per dataset [21]. The 95 % confidence interval around the mean costs was determined by taking the 2.5th and the 97.5th percentile of these bootstrap replications. Costs were calculated for the total study population.
Results
Demographics
The 14 participating hospitals registered 592 consecutive patients with a femoral neck fracture, of whom 181 were eligible and 150 (25 %) subsequently gave informed consent (Fig. 1). One patient withdrew consent immediately, one patient died before surgery, and seven patients were treated with internal fixation rather than arthroplasty. A total of 141 patients remained for the current cost analysis, of whom 74 were treated with hemiarthroplasty and 67 with a total hip arthroplasty. The mean age was 81 (SD 7; range 57–100) years, 2 patients (1 %; both females) were younger than 60 years of age. A total of 96 patients (68 %) were female. The mean age was 80 (SD 8; range 57–100) years for females and 81 (SD 6; range 69–91) years for males. No patients (0 %) had ASA class 1 or class 5, 67 (48 %) patients had ASA class 2, 72 (51 %) ASA class 3, and 2 (1 %) ASA class 4. A total of 136 (97 %) patients were not institutionalized before the fracture, and 102 (72 %) patients were independently ambulatory before the fracture.
Fig. 1
Flow-chart of patient enrollment process. *Patients could meet more than one exclusion criterion
×
Clinical outcome and health care consumption
The mean duration of hospital admission was 10 days (SD 8). One patient with a complicated clinical course was discharged at 90 days after the initial surgery. Within 14 days after surgery, 87 % (N = 123) of the patients were discharged. The discharge destination was a rehabilitation or nursing facility in 56 % of patients, and 44 % of patients went to their own house. Median stay per patient was 10 days (SD 28) in a rehabilitation facility, 14 days (SD 42) in a nursing facility, and 18 days (SD 62) in an elderly home. During rehabilitation, patients had a mean of 52 (SD 5) physical therapy sessions per patient.
A total of 118 adverse events (AEs) occurred; 77 patients (55 %) had no AE at all. The most frequent AEs were a subsequent fracture (N = 19; 13 %), a superficial wound infection (N = 11; 8 %), and dislocations (N = 10; 7 %). Less than ten patients had other AEs including pulmonary embolism, myocardial infarction, cerebral vascular accident, pneumonia, urinary tract infection, delirium, or decubitus. Eighteen revision surgeries were performed in ten patients (Table 2). Dislocation was treated ten times; seven closed reductions were done in the emergency department, two in the operating room. One patient underwent an open reduction. Three conversions from hemiarthroplasty to total hip arthroplasty were performed. One patient suffered three dislocations after the conversion. One patient underwent an arthrotomy and joint lavage three times to treat a deep infection. One periprosthetic fracture was treated with plating. The 10-week mortality was 5 % (N = 7), the 1-year mortality was 11 % (N = 16), and the 2-year mortality was 19 % (N = 27). Patients died mainly due to cancer (N = 9), cardiovascular diseases (N = 6), neurological diseases (N = 3), and the bone cement implantation syndrome (N = 2). The mean duration of follow-up was 22 months (SD 9).
Table 2
List of revision surgeries performed
Revision surgery 1
Revision surgery 2
Revision surgery 3
Revision surgery 4
Patient 1
Conversion to THA
Closed reduction ED
Closed reduction ED
Closed reduction ED
Patient 2
Arthrotomy and joint lavage
Arthrotomy and joint lavage
Arthrotomy and joint lavage
Patient 3
Closed reduction ED
Closed reduction ED
Plate fixation periprosthetic frx
Patient 4
Closed reduction OR
Closed reduction ED
Patient 5
Conversion to THA
Patient 6
Open reduction
Patient 7
Closed reduction ED
Patient 8
Arthrotomy
Patient 9
Conversion to THA
Patient 10
Closed reduction OR
THA, total hip arthroplasty; ED, emergency department; OR, operating room
Costs
ESM Supplemental Table 3 shows the fraction of patients who used health care and the volume of health care use per user. These data were not imputed. Table 3 shows the calculated mean costs for used health care after multiple imputations of the missing data. The overall percentage of missing data was 17.8 % and the relative efficiency of the multiple imputations was 0.98. In the first 10 weeks after the fracture the mean total costs was €15,216, which was 58 % of the total costs. The most important cost category was primary hospital stay accounting for €9026. From this category, costs were predominantly related to hospital admission (€5732) and index surgery (€2915). Other important costs were incurred for rehabilitation facilities and nursing homes (€4707).
Table 3
Mean costs of femoral neck fracture patients treated with hemi- or total hip arthroplasty (N = 141)
Cost categories
Cost until 10 weeks (€)
Costs until 1 year (€)
Costs until 2 years (€)
A) Hospital costs—primary stay
Emergency department visit
160 (160–160)
160 (160–160)
160 (160–160)
Radiology/diagnostic modalities
219 (206–232)
219 (206–232)
219 (206–232)
Surgery
2,915 (2,798–3,023)
2,915 (2,798–3,023)
2,915 (2,798–3,023)
Admission days
5,732 (4,452–7,966)
5,732 (4.452–7,966)
5,732 (4,452–7,966)
Total
9,026 (7,706–11,295)
9,026 (7,706–11,295)
9,026 (7,706–11,295)
B) Hospital costs—follow-up
Radiology/diagnostic modalities
115 (103–128)
240 (212–270)
344 (278–427)
Outpatient clinic visits
120 (109–133)
297 (263–336)
416 (355–494)
Adverse events
200 (66–392)
581 (280–1,056)
1,052 (568–1,781)
Revision surgery
396 (61–990)
480 (112–1,100)
980 (345–1,940)
Medication
82 (74–92)
106 (93–121)
151 (125–182)
Total
914 (499–1,541)
1,705 (1,102–2,563)
2,943 (1,894–4,308)
C) Costs related to rehabilitation/changes in living situation
Rehabilitation center/nursing home
4,707 (3,627–5,874)
11,694 (8,132–16,350)
12,240 (8,542–17,008)
Physical therapy (outpatient)
549 (470–640)
1,340 (1,162–1,537)
1,975 (1,627–2,370)
Use of aids
20 (17–25)
105 (78–139)
214 (166–270)
Total
5,276 (4,200–6,467)
13,138 (9,486–17,956)
14,429 (10,461–19,552)
D) Total costs
15,216 (13,051–18,323)
23,869 (19,157–30,136)
26,399 (21,101–33,213)
Costs are presented as mean costs at each follow-up moment with 95 % uncertainty interval between brackets
The data have been imputed. If a patient had not consumed health care, costs for that item were recorded as €0
At 1 year of follow-up, the mean total costs per patient was €23,869 (95 % CI €19,157–€30,136), this was 90 % of the overall total costs. Fifty-five percent of costs were spent on rehabilitation and changes in living situation with a total amount of €13,138. Rehabilitation centers/nursing homes (€11,694) and physical therapy at the outpatient clinic (€1340) were the main cost determinants. After 2 years of follow-up, the total rehabilitation-related costs (€14,429) still accounted for 55 % of the total costs. The hospital costs for follow-up almost doubled from €1705 (7 % of the total costs) after 1 year to €2943 (11 %) after 2 years of follow-up. The main items were costs related to adverse events which increased by 181 % from €581 to €1052 and a 204 % increase in costs for revision surgery from €480 to €980 (Fig. 2).
Fig. 2
Relative contribution of costs categories to the total treatment costs of patients until 2 years of follow-up
×
Anzeige
Discussion
The mean total costs per patient after treatment with hemi- or total hip arthroplasty for femoral neck fracture were €23,869 (95 % CI €19,157–€30,136) at 1 year and €26,399 (95 % CI €21,101–€33,213) at 2 years after a fracture.
These costs are in line with the range of €12,952 to €43,671 (as adjusted to 2012) found in literature [8‐10, 22‐27]. This broad range can be explained by different variables used in the studies. All studies were performed in western countries, but with different health care systems, mean length of hospital stay, reference costs, and rehabilitation facilities. The populations studied had a relatively small sample size ranging from 32 to 180 patients. One study, involving 19,808 patients, used a Markov decision model [22]. Although most of the costs are generated in the first year, the two studies with the lowest costs had a follow-up of 1 year [23, 25], not taking into consideration the late and costly complications. One study [9] did not include treatment with hemiarthroplasty and two studies only reviewed the costs for patients treated with hemiarthroplasty [23, 24]. Also, previous studies used different types of costs e.g., in-hospital costs only [8], the included populations differed in age, or included only women [25]. Results of the current study correspond best with the results of the two largest studies (adjusted costs €29,834 and €29,807, respectively), both including both types of arthroplasty [10, 22].
In addition, from a prospective cohort study of 10,275 Dutch persons, the estimated incremental costs of medical care were $9540 (adjusted to € in 2012: €11,715) in the first year after a hip fracture and $1017 (€1248) in the subsequent year [28]. These incremental costs are comparable with the €14,844 (first year) and €2529 (subsequent year) found in the current study. De Laet et al. [28] found higher costs, but that study did not include detailed costs of adverse events, revision surgeries, and costs of diagnostic modalities. The in-depth method of our study can be considered more specific as the total costs are presented in more detail.
Recently, a similar study was published involving Dutch elderly patients with a femoral neck fracture (50 years or older) who were primarily treated with internal fixation [16]. Both studies had the same design and used identical research methods, questionnaires, statistics, and resources, making it suitable for direct comparison. After two years of follow-up the costs, adjusted to 2012 for the total internal fixation group were €20,368 (original data: €19,425; 95 % CI €5,237–€58,874). The relative contributions of the different cost categories were very comparable with respect to rehabilitation (46 % of total costs for arthroplasty and 49 % for internal fixation) and hospital admission days (both 22 %), with higher absolute costs in the current arthroplasty study. These differences can be explained by the generally older population in the arthroplasty group based on baseline characteristics. In the current study, the mean age was 10 years older (81 versus 71), patients were more often ASA 3–4 (54 versus 13 %), used aids pre-fracture more often (28 versus 13 %), and had a displaced fracture more often (100 versus 46 %). It is likely that older patients are admitted to a rehabilitation facility more often longer. Moreover, the mean number of hospital admission days (10 versus 7 days) was longer in the arthroplasty group. Subgroup analysis of 67 patients (27 %) who underwent revision to arthroplasty after primary internal fixation resulted in adjusted costs of: €28,031 (€26,733; 95 % CI €9465–€80,029), which exceeds the costs of primary arthroplasty. This emphasizes the need to carefully select primary treatment for hip fractures as conversion from internal fixation to arthroplasty is even more costly than primary arthroplasty.
Anzeige
This study had some limitations. First, the population has been selected, based upon the eligibility for arthroplasty. Therefore it is a specific subset of the total population which presented to the emergency department of the participating hospitals. The patients were relatively healthy, fit, and most were independent walkers before the fracture. Patients with dementia or Parkinson’s disease were excluded, but these patients represent a substantial part of the general hip fracture population. These patients may have complex needs and incur higher costs, consequently leading to an underestimation of the mean costs presented. Costs are based on Dutch prices and may vary depending on the health care system used. However, by comparing with published costs from other Western countries, we showed that the results are applicable to other settings as well. Secondly, the actual costs are expected to be even higher as costs for pre-hospital care, costs for routine blood analysis at the emergency department and wards, and perioperative consultation by other medical specialists and, although not routinely applied, forensic autopsy were not included. On the other hand, the number of visits for follow-up and X-rays are lower in general practice than in a trial setting. Also, the amounts used in the cost price manuals used may differ from the actual costs. However, these costs are not expected to be substantial. Finally, costs for home care and general practitioner (GP) visits were not included as for most patients it was impossible to discriminate which part of the post-fracture home care and GP visits was actually due to the hip fracture and not due to care for other pre- or post-fracture conditions. With these limitations in mind the results of the current study are in line with previous international publications.
In conclusion, the treatment of displaced femoral neck fractures with hemi- or total hip arthroplasty is costly with mean total costs after one year of €23,869 and €26,399 after 2 years of follow-up. Rehabilitation and nursing homes account for almost half of the total medical costs, revision surgery, and adverse events not even 10 %. Focus on improvements of the rehabilitation phase can result in reducing costs.
Acknowledgments
Steering Committee: Mohit Bhandari (Chair), PJ Devereaux, Thomas A. Einhorn, Lehana Thabane, Emil H. Schemitsch, Kenneth J Koval, Frede Frihagen, Rudolf W. Poolman, Kevin Tetsworth, Ernesto Guerra-Farfán, Stephen D. Walter, and Gordon H Guyatt.
Global Methods Centre: Mohit Bhandari (Principal Investigator); Sheila Sprague (Research Program Manager); Kim Madden, Paula McKay, Marilyn Swinton, and Taryn Scott, (Project Management); Diane Heels-Ansdell, (Statistical Analysis); and Lisa Buckingham and Aravin Duraikannan (Data Management) (McMaster University).
Anzeige
US Methods Centre: Thomas A. Einhorn (Principal Investigator) and Heather Silva (Research Coordination) (Boston University Medical Center).
Netherlands Methods Centre: Rudolf W. Poolman (Principal Investigator), Martin J. Heetveld (Co-Principal Investigator); Esther M.M. Van Lieshout (Research Coordination), and Paul T.P.W. Burgers (Trial Coordination) (Erasmus Medical Centre, Rotterdam).
Central Adjudication Committee: Mohit Bhandari (Chair), Robert D. Zura, Emil H. Schemitsch, Victoria Avram, Ajay Manjoo, and Dale Williams.
Data Safety Monitoring Board (CIHR): John Antoniou (Chair), Tim Ramsay, Earl R. Bogoch, and Andrew Trenholm.
Data Safety Monitoring Board (NIH): Stephen Lyman (Chair), Madhu Mazumdar, Kevin J. Bozic, Mark Luborsky, Stuart Goodman, and Susan Murray.
HEALTH Investigators
The following persons participated in the HEALTH trial:
Canada
University of Calgary, Foothills Medical Centre—Rob Korley, Richard Buckley, Paul Duffy, Shannon Puloski, Kimberly Carcary, Melissa Lorenzo, Georgia Carstensen, and Ross McKercher; University of Calgary, Rockyview General Hospital—Kelly Johnston, Greg Abelseth, Raul Kuchinad, and Saboura Mahdavi; St. Michael’s Hospital—Emil H. Schemitsch, Michael D. McKee, Jeremy A. Hall, Aaron Nauth, Daniel Whelan, Timothy R. Daniels, Earl R. Bogoch, James P Waddell, Henry Ahn, Milena R. Vicente, Jennifer T. Hidy, and Melanie T. MacNevin; Sunnybrook Health Sciences Centre—Hans Kreder, Terry Axelrod, Richard Jenkinson, Markku Nousiainen, David Stephen, Veronica Wadey, Monica Kunz, Katrine Milner, Ria Cagaanan, and Melanie MacNevin; Vancouver General Hospital—Peter J. O’Brien, Piotr A. Blachut, Henry M. Broekhuyse, Pierre Guy, Kelly A. Lefaivre, Gerard P. Slobogean, Raman Johal, and Irene Leung; Queen Elizabeth II Health Sciences Centre—Chad Coles, Ross Leighton, C. Glen Richardson, Michael Biddulph, Michael Gross, Michael Dunbar, J. David Amirault, David Alexander, Catherine Coady, Mark Glazebrook, David Johnston, William Oxner, Gerald Reardon, Ivan Wong, Kelly Trask, and Shelley MacDonald; Memorial University of Newfoundland—Andrew Furey, Craig Stone, and Minnie Parsons; University of British Columbia/Fraser Health Authority—Trevor Stone, Mauri Zomar, Robert McCormack, Kelly Apostle, Dory Boyer, Farhad Moola, Bertrand Perey, Darius Viskontas, Karyn Moon, and Raely Moon; Hôpital du Sacré-Coeur de Montréal—Yves Laflamme, Benoit Benoit, Pierre Ranger, Michel Malo, Julio Fernandes, Karine Tardif, and Julie Fournier; Hôpital Maisonneuve-Rosemont—Pascal André Vendittoli, Vincent Massé, Alain G. Roy, Martin Lavigne, and Daniel Lusignan; Hôpital Saint-François d’Assise—Etienne L Belzile, and Pascale Levesque-Bernier; Hôpital de l’Enfant Jésus—Etienne L Belzile, Luc Bédard, and Pascale Levesque-Bernier; and Lakeridge Health—Samir Chhabra, Kelly Fusco.
United States
Colorado Orthopedic Consultants—Craig Davis, Philip Stull, Stewart Weinerman, Peter Weingarten, Steven Lindenbaum, Michael Hewitt, Rebecca Danielwicz, and Janell Baker; Rubin Institute for Advanced Orthopaedics—Michael Mont, Donald E. Delanois, Bhaveen Kapadia, Kimona Issa, and Marylou Mullen; Mayo Clinic—Andrew Sems and Barb Foreman; Rothman Institute—Javad Parvizi and Tiffany Morrison; Orthopaedic Associates of Hartford—Courtland Lewis and Stephanie Caminiti; Boston University Medical Center—Thomas A Einhorn, Paul Tornetta III, William R Creevy, Heather Silva, Michelle J. Lespasio, adn Hope Carlisle; Lahey Clinic—Andrew Marcantonio, Michael Kain, Lawrence Specht, and John Tilzey, and John Garfi; University of Pennsylvania—Samir Mehta, John L. Esterhai Jr, Jaimo Ahn, Derek Donegan, Annamarie Horan, and Kelly McGinnis; Emory University School of Medicine—James Roberson, Thomas Bradbury, Greg Erens, and Kyle Webb; Indiana University—Brian Mullis, Karl Shively, Andrew Parr, Janos Ertl, Ripley Worman, Mark Webster, Judd Cummings, Valda Frizzell, and Molly Moore; Orthopaedic Associates of Michigan—Clifford B. Jones, James R. Ringler, Debra L. Sietsema, and Jane E. Walker; Texas Tech University—Enes Kanlic, Amr Abdelgawad, and Juan Shunia; Mission Hospital Research Institute—Charles DePaolo, Susan Sutherland, and Rachel Alosky; Duke University Medical Center—Robert Zura and Maria Manson; Park Nicollet Institute—Gregg Strathy, Kathleen Peter, Paul Johnson, and Meaghan Morton; St. Elizabeth Health Center—James Shaer, Tyson Schrickel, Barbara Hileman, Marina Hanes, and Elisha Chance; Texas Institute for Hip and Knee Surgery—E. Matthew Heinrich, David Dodgin, and Michele LaBadie; University of California Irvine—David Zamorano, Martin Tynan, Ran Schwarzkopf, John A Scolaro, Ranjan Gupta, Samuel Bederman, Nitin Bhatia, Bang Hoang, Douglas Kiester, Neil Jones, Gregory Rafijah, Damon Alavekios, Jason Lee, Akshay Mehta, Steven Schroder, Tom Chao, Vincent Colin, Phuc (Phil) Dang, Stephen Keun Heng, Gregory Lopez, Samuel Galle, Sohrab Pahlavan, Duy L Phan, Minal Tapadia, Christopher Bui, Nickul Jain, Tyler Moore, Nathan Moroski, and Deeba Pourmand; University of Utah—Erik N. Kubiak, Jeremy Gililland, David Rothberg, Christopher Peters, Christopher Pelt, Ami R. Stuart, and Kirby Corbey; Marshall University—Franklin D. Shuler, James Day, Tigran Garabekyan, Felix Cheung, Ali Oliashirazi, Jonathon Salava, Linda Morgan, Timothy Wilson-Byrne, and Mary Beth Cordle; Allegheny Hospital—Timothy J Sauber, Edward Westrick, Robert Duerr, Michael Maher, and Traci Salopek; University Orthopaedic Associates—Carlos A Sagebien, David A Harwood, Stephen Kayiaros, and Patricia Seuffert; State University of New York at Buffalo (UBMD Orthopaedics and Sports Medicine)—Sridhar Rachala, Mark Anders, Christopher Mutty, Matthew Philips, Allison Cornwall, and Mary Bayers-Thering; and University of Arizona—Michael Dohm, and Cindy Fastje
Netherlands
Amphia Ziekenhuis—Leon H.G.J. Elmans, Joost A.A.M. van den Hout, Adrianus J.P. Joosten, Ad F.A. van Beurden, Stefan B.T. Bolder, Denise Eygendaal, Adrianus F.C.M. Moonen, Rutger C.I. van Geenen, Eric A. Hoebink, Robert Wagenmakers, and Wouter van Helden; Deventer Ziekenhuis—Ydo V Kleinlugtenbelt, Hans-Peter W. van Jonbergen, Herbert Roerdink, Joost M. Reuver, Alexander F.W. Barnaart, and Elvira R. Flikweert; Diaconessenhuis Leiden—Rover Krips, J. Bernard Mullers, and Hans Schüller; Flevoziekenhuis—Mark L.M. Falke, Frans J. Kurek, and Adrianus C.H. Slingerland; Gelderse Vallei—Jan P. van Dijk and Wouter H. van Helden; Gelre Ziekenhuizen—Hugo W. Bolhuis, Pieter H.J. Bullens, Mike Hogervorst, Karin E . de Kroon, Rob H . Jansen, Ferry Steenstra, and Eric E.J. Raven; IJsselland Ziekenhuis—W. Peter J. Fontijne, Saskia C. Wiersma, Bastiaan Boetes, and Edgar J.T. ten Holder; Leids Universitair Medisch Centrum—Huub J.L. van der Heide, Jochem Nagels, and Enrike H.M.J. van der Linden-van der Zwaag; Medisch Centrum Haaglanden—Stefan B. Keizer, Jan-Willem A. Swen, Peter H.C. den Hollander, and Bregje J.W. Thomassen; OLVG—Rudolf W. Poolman, Willem Jan Kleyn Molekamp, Frank R.A.J. de Meulemeester, Arthur E.B. Kleipool, Robert Haverlag, Maarten P. Simons, and Eduard L.A.R. Mutsaerts; Ruwaard van Putten Ziekenhuis—Rob Kooijman, Roelf R. Postema, René J.T.M. Bleker, and Harald I.H. Lampe; Slotervaartziekenhuis—Lein Schuman, John Cheung, Frank van Bommel, W. Paul C.A. Winia, Daniel Haverkamp, and Harm van der Vis; Spaarne Ziekenhuis—Peter A. Nolte, Michel P.J. van den Bekerom, Tjitte de Jong, Arthur van Noort, Diederik A. Vergroesen, and Bernard G. Schutte; and Tergooiziekenhuizen—Harm M . van der Vis, Lijkele Beimers, Jasper de Vries, Arthur W. Zurcher, G.H. Rob Albers, Maarten Rademakers, Stefan Breugem, Ibo van der Haven, Pieter Jan Damen, Gythe H. Bulstra, Martin M. Campo, Mathijs P. Somford, and Daniël Haverkamp.
International
The Alfred—Susan Liew, Harvinder Bedi, Ashley Carr, Andrew Chia, Steve Csongvay, Craig Donohue, Stephen Doig, Elton Edwards, Max Esser, Richard Freeman, Andrew Gong, Doug Li, Russell Miller, Lu Ton, Otis Wang, Ian Young, Adam Dowrick, Zoe Murdoch, and Claire Sage; Oslo University Hospital—Frede Frihagen, Lars Nordsletten, John Clarke-Jenssen, Geir Hjorthaug, Anne Christine Brekke, and Elise Berg Vesterhus, Ringerike Sykehus Hospital—Ingunn Skaugrud; Hospital Universitario Costa del Sol—Enrique Guerado, Encarnacion Cruz, and Juan Ramon Cano; Hospital Dr. Josep Trueta—Miguel Angel Froufe, Lluis Marull Serra, Samer Al-dirra, and Cristina Martinez; The Geelong Hospital—Richard Page, David Bainbridge, Richard Angliss, Ben Miller, Andrew Thomson, Graeme Brown, Simon Williams, Kevin Eng, David Bowyer, John Skelley, Chatar Goyal, and Sally Beattie; Hospital de la Ribera—Francisco José Tarazona Santabalbina; Vall d’Hebron University Hospital—Ernesto Guerra-Farfán, Jordi Teixidor Serra, Jordi Tomas Hernandez, Marc Aguilar Garcia, Vicente Molero Garcia, Sergi Barrera, Jordi Selga, Teresa Sanclemente, Maria Villar, Joan Bago, and Miriam Garrido; James Cook University Hospital—Amar Rangan, Birgit Hanusch, Lucksy Kottam; North Shore Hospital—William Farrington and Carol Greene; and University Hospital 12 de Octubre—José A Moreno Beamud, Pedro Caba Doussoux, Rafael Navarro, Arantxa Capel, and Emilio Delgado
Compliance with ethical standards
Conflicts of interest
None.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Funding
Members of the research team received a grant from The Netherlands Organization for Health Research and Development (ZonMw; grant number 17088.2503), Canadian Institutes of Health Research (CIHR; grant number MCT-90168) and National Institutes of Health (NIH; grant number 1R011AR055130-01A1). The funding agencies were not involved in the study design, data collection, data analysis, manuscript preparations or publication decisions for this manuscript.
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Total medical costs of treating femoral neck fracture patients with hemi- or total hip arthroplasty: a cost analysis of a multicenter prospective study
verfasst von
P. T. P. W. Burgers M. Hoogendoorn E. A. C. Van Woensel R. W. Poolman M. Bhandari P. Patka E. M. M. Van Lieshout on behalf of the HEALTH trial investigators
In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.
Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Update Orthopädie und Unfallchirurgie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
